Agile Therapeutics (NASDAQ:AGRX) Downgraded to Sell at Zacks Investment Research

Share on StockTwits

Agile Therapeutics (NASDAQ:AGRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, reports.

According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. “

AGRX traded down $0.06 during trading on Tuesday, reaching $1.72. The company had a trading volume of 39,136 shares, compared to its average volume of 1,458,367. The company has a quick ratio of 10.18, a current ratio of 10.18 and a debt-to-equity ratio of 0.24. The business has a 50 day simple moving average of $1.97 and a 200-day simple moving average of $2.66. The stock has a market cap of $151.81 million, a P/E ratio of -3.38 and a beta of 1.32. Agile Therapeutics has a 52 week low of $1.70 and a 52 week high of $3.89.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Sunday, February 28th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $1.01 million. As a group, equities research analysts expect that Agile Therapeutics will post -0.64 EPS for the current fiscal year.

In other Agile Therapeutics news, CFO Dennis Reilly purchased 50,000 shares of Agile Therapeutics stock in a transaction dated Tuesday, March 23rd. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $102,500.00. Following the completion of the acquisition, the chief financial officer now owns 156,306 shares in the company, valued at approximately $320,427.30. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have acquired 72,500 shares of company stock valued at $147,573 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of AGRX. BlackRock Inc. increased its stake in Agile Therapeutics by 0.3% in the 4th quarter. BlackRock Inc. now owns 5,121,965 shares of the specialty pharmaceutical company’s stock worth $14,699,000 after buying an additional 17,539 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Agile Therapeutics by 80.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 1,568,645 shares of the specialty pharmaceutical company’s stock worth $4,502,000 after acquiring an additional 698,725 shares during the period. Needham Investment Management LLC purchased a new position in shares of Agile Therapeutics during the fourth quarter worth approximately $1,722,000. Brandywine Global Investment Management LLC bought a new stake in shares of Agile Therapeutics during the fourth quarter valued at approximately $595,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Agile Therapeutics by 254.7% in the fourth quarter. JPMorgan Chase & Co. now owns 169,247 shares of the specialty pharmaceutical company’s stock valued at $485,000 after purchasing an additional 121,537 shares during the period. 44.44% of the stock is owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.